Skip to main content
. 2014 Sep 4;2014(9):CD006647. doi: 10.1002/14651858.CD006647.pub4

Comparison 1. No anthracyclines versus anthracyclines.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analysis) 10   Hazard Ratio (Random, 95% CI) Subtotals only
1.1 ALL 3 912 Hazard Ratio (Random, 95% CI) 1.22 [0.95, 1.57]
1.2 Wilms' tumour 3 316 Hazard Ratio (Random, 95% CI) 1.85 [1.09, 3.15]
1.3 Rhabdomyosarcoma/undifferentiated sarcoma 2 409 Hazard Ratio (Random, 95% CI) 1.04 [0.83, 1.29]
1.4 Hepatoblastoma 1 255 Hazard Ratio (Random, 95% CI) 1.14 [0.41, 3.16]
1.5 AML 1 394 Hazard Ratio (Random, 95% CI) 1.16 [0.94, 1.44]
2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analysis) 7   Hazard Ratio (Random, 95% CI) Subtotals only
2.1 ALL 2 870 Hazard Ratio (Random, 95% CI) 1.05 [0.76, 1.46]
2.2 Wilms' tumour 3 316 Hazard Ratio (Random, 95% CI) 2.21 [1.44, 3.40]
2.3 Non‐Hodgkin lymphoma 1 284 Hazard Ratio (Random, 95% CI) 1.01 [0.74, 1.38]
2.4 Hepatoblastoma 1 255 Hazard Ratio (Random, 95% CI) 0.81 [0.42, 1.55]
3 Tumour response 5   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
3.1 ALL 2 870 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.99, 1.06]
3.2 Rhabdomyosarcoma / undifferentiated sarcoma 1 413 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.91, 1.09]
3.3 Hepatoblastoma 1 255 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.96, 1.08]
3.4 AML 1 394 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.75, 1.01]
4 Clinical cardiotoxicity 3   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
4.1 Cardiac death 2 410 Risk Ratio (M‐H, Random, 95% CI) 0.41 [0.04, 3.89]
4.2 Cardiotoxicity grade 3 or 4 according to NCICTC version 2 1 394 Risk Ratio (M‐H, Random, 95% CI) 0.2 [0.02, 1.70]
5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis) 2 275 Hazard Ratio (Random, 95% CI) 1.27 [0.77, 2.11]
5.1 Stage II‐III FH and UH 1 227 Hazard Ratio (Random, 95% CI) 1.16 [0.62, 2.18]
5.2 Stage IV 1 48 Hazard Ratio (Random, 95% CI) 1.51 [0.65, 3.50]
6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis) 2 275 Hazard Ratio (Random, 95% CI) 1.72 [1.09, 2.72]
6.1 Stage II‐III FH and UH 1 227 Hazard Ratio (Random, 95% CI) 1.80 [1.04, 3.12]
6.2 Stage IV 1 48 Hazard Ratio (Random, 95% CI) 1.54 [0.66, 3.57]